By otakuyassine3@gmail.com 
OptimizeRx (NASDAQ:OPRX – Free Report) had its price target decreased by B. Riley from $17.00 to $13.00 in a research report released on Tuesday morning,Benzinga reports. B. Riley currently has a buy rating on the stock.
OPRX has been the subject of a number of other research reports. Roth Mkm reiterated a “buy” rating and set a $16.00 price objective (down previously from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. JMP Securities reduced their target price on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a report on Thursday, November 14th. Royal Bank of Canada dropped their price target on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Stifel Nicolaus reduced their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, William Blair reissued an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.19.
Read Our Latest Stock Analysis on OPRX
OptimizeRx Stock Up 4.7 %
OPRX stock opened at $5.17 on Tuesday. The firm has a market cap of $95.24 million, a PE ratio of -3.89 and a beta of 1.34. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $16.65. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. The firm has a 50 day simple moving average of $5.25 and a 200 day simple moving average of $7.65.
Insider Buying and Selling
In other news, CEO William J. Febbo acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the acquisition, the chief executive officer now owns 601,253 shares in the company, valued at approximately $3,012,277.53. The trade was a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of OPRX. Rice Hall James & Associates LLC lifted its holdings in shares of OptimizeRx by 24.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after buying an additional 119,306 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in OptimizeRx in the third quarter valued at approximately $810,000. First Light Asset Management LLC grew its position in OptimizeRx by 5.1% in the second quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after acquiring an additional 89,377 shares in the last quarter. Bullseye Asset Management LLC grew its position in OptimizeRx by 55.6% in the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after acquiring an additional 76,458 shares in the last quarter. Finally, Essex Investment Management Co. LLC increased its stake in shares of OptimizeRx by 42.9% during the 3rd quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company’s stock worth $1,868,000 after purchasing an additional 72,672 shares during the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.
OptimizeRx Company Profile
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
See Also
Receive News & Ratings for OptimizeRx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OptimizeRx and related companies with MarketBeat.com’s FREE daily email newsletter.